- SciSparc Secures Strategic Advantage with Grant of European Patent
- SciSparc to Acquire AutoMax
- SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
- SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
- SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
- SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
- SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
- SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
- SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
- SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.80 |
---|---|
High | 0.809 |
Low | 0.75 |
Bid | 0.7518 |
Offer | 0.78 |
Previous close | 0.8001 |
Average volume | 49.65k |
---|---|
Shares outstanding | 708.44k |
Free float | 708.27k |
P/E (TTM) | -- |
Market cap | 532.75k USD |
EPS (TTM) | -1.22 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 20:58 BST.
More ▼